IVF/ART/Infertility

FRIDAY, NOVEMBER 22

08:30-10:00 AMH vs AFC…AND THE WINNER IS……?
Hall A
Capsule What is the role of AMH in the diagnosis and treatment of infertility?
Chairpersons Scott Nelson, Scotland
Nick Macklon, UK
08:30-09:15 Debate: Is AMH a good predictor for success in IVF cycles?
Pro: Antonio La Marca, Italy
Con: Joop Laven, Netherlands
09:15-10:00 Debate: Are we really misinforming young women on their reproductive potential by using AMH and AFC testing?
Yes: Edgardo Somigliana, Italy
No: Antonio La Marca, Italy
10:20-11:50 PCOS/PCO
Hall A
Capsule PCOS is considered the most common endocrine disorder in reproductive age. However, the prevalence (6.5-17.8%), as well as the long-term risks, vary widely with the diagnostic tests and criteria. Should we change the criteria?
Chairpersons Roger A. Lobo, USA
Zion Ben Rafael
, Israel
10:20-11:05 Debate: Androgens are the villain in PCOS
Con: Joop Laven, Netherlands
Pro: Jerome Strauss, USA
11:05-11:50 Debate: We must screen PCOS cases for the presence of the metabolic syndrome
Pro: Bart Fauser, Netherlands
Con: Phillippe Bouchard, France
12:10-13:40 FIBROIDS: MEDICAL, SURGICAL, OR “NO TOUCH TECHNIQUE” TO TREAT SMALL FIBROIDS BEFORE IVF
Hall A
Capsule The association of fibroids and infertility is well established. However, the issue of if, when and how to treat needs clarification. Does medical option change the current paradigm?
Chairpersons Jacques Donnez, Belgium
Olivier Donnez, Belgium
12:10-12:30 Surgical or medical treatment before IVF?
Jasper Verguts, Belgium
12:30-12:55 No treatment before IVF is needed for intramural smaller than 3-cm fibroids
Roberto Marci, Switzerland
12:55-13:15 Fibroids and UPA: How to explain the good and bad responders
Marie Madeleine Dolmans, Belgium
13:15-13:40 Leiomyoma or leiomyosarcoma? How can we tell?
Herve Fernandez, France
14:30-16:30 STIMULATION, OOCYTES AND EMBRYOS
Hall A
Capsule Stimulation, the first step in IVF, has never had consensus..
Chairpersons Rene Frydman, France
14:30-15:00 Debate: Ovarian stimulation More or Less?
Less is more: Geeta Nargund UK
No! New twists in ovarian stimulation: More is better: Dominique de Ziegler, France
15:00-15:20 GnRH agonists and IVF: The end …. or not?
Joelle Belaisch Allart, France
15:20-15:40 The numbers of small (2-5 and 6-9 mmm) follicles are inversely correlated in both normal women and in PCOS: What is the missing link?
Sophie Catteau-Jonard, France
15:40-16:30 COGI SPECIAL CONTROVERSIAL SYMPOSIA
Capsule The next stage in improving the result, is understanding what’s wrong with what we’re doing
15:40-16:05 RCTs may not be the answer to all outstanding questions in IVF
Bart Fauser, Netherlands
16:05-16:30 Repeated implantation failure:  An iatrogenic phenomenon which leads to two unnecessary activities
Zion Ben Rafael, Israel
16:50-18:20 ADENOMYOSIS AND ENDOMETRIOSIS
Hall A
Capsule The concept that uterine adenomyosis and pelvic endometriosis as well as endometriotic lesions at distant sites of the body share a common pathophysiology with endometriosis was promoted almost a decade ago. What is the current thinking?
Chairpersons Marie-Madeline Dolmans, Belgium
Philippe Descamps, France
16:50-17:10 Adenomyosis and deep endometriosis: Two linked diseases?
Jacques Donnez, Belgium
17:10-17:45 Debate: The endometrioma and the ovarian reserve: The challenge of the surgeon
To operate first: Herve Fernandez, France
ART before operation: Edgardo Somigliana, Italy
17:45-18:20 Debate: Deep-endometriosis should be operated prior to ART
Pro for surgery first: Olivier Donnez, Belgium
Cons for IVF first (against surgery): Pietro Santulli, France

SATURDAY, NOVEMBER 23

08:30-10:00 PGT-A
Hall A
Capsule Is PGS useful or harmful?
Chairpersons Simon Fishel, UK
Gerald Schatten, USA
08:30-08:55 PGT-A for Advances maternal age and repeated abortions, useful or harmful?
Santiago Munne, USA
08:55-09:15 RCT of PGT for aneuploidy by microarray of polar body in advance maternal age. Any advantage? The Esteem Study
Luca Ginaroli, Italy
09:15-09:35 Euploidy in donor eggs varies greatly between centers
Santiago Munne, USA
09:35-10:00 PGD/PGT-A without embryo biopsy, is this the answer?
Samir Hamamah, France
10:20-11:50 INDUSTRY SUPPORTED SESSION
Supported by Reprocare Genetics Scandinavia
Hall A
12:10-13:40 QUESTIONS AND ANSWER FROM HALL A AND B
Hall A
Chairpersons Zion Ben Rafael¸ Israel
Rene Frydman, France
Bart Fauser, Netherlands
Discussants  
  • Progesterone: Should we measure it during the follicular phase and on the day of ET?
  • LH or hCG: Which is more important for ovarian stimulation
  • Letrozole as first line ovulation induction treatment for PCOS. Is the evidence strong enough?
  • Significance of elevated late follicular phase Progesterone in IVF
  • Current status of ovarian stimulation pre-treatment strategies
  • For how long should luteal phase supplementation in IVF be continued?
  • Freeze all embryos strategies in IVF for all
  • In which selected patient populations is PGT-A proven beneficial
  • In which infertile patients should expectant management be advocated
  • Pros and cons of motherhood at more advanced female age
  • For which patient categories may endometrial gene testing be beneficial
  • Will IVF patients benefit from newly developed microbiome strategies?
  • Fibroids
  • Endometriosis
14:30-16:30 HITECH IVF:  ARTIFICIAL GAMETE
Hall A
Capsule Current capability promise more ethical questions.
Chairpersons Dominique De Ziegler, France
14:30-14:50 Conception versus manufacturing:  ART Prospects with artificial gametes and assembled embryos
Gerald Schatten, USA
14:50-15:15 Artificial ovary
Marie Madeleine Dolmans, Belgium
15:15-15:40 Expanding PGT to polygenic risk
Nathan Treff, USA
15:40-16:00 Can IVF influence human evolution?
Hans Ivar Hanevik, Norway
16:00-16:30 Special countercurrent lecture:
Are we overusing IVF
Fulco van der Veen, Netherlands
16:50-18:20 FREEZE ALL
Hall A
Capsule Freeze only strategy became popular before any study to its efficacy appeared. Now that RCTs failed to proof of its usefulness to all, it’s time to discuss the overall advantages and disadvantages
Chairpersons Amelia Rodríguez-Aranda, Spain
Jacques Donnez, Belgium
16:50-17:20 Debate: Freeze only strategy for all?
Con: Ben Mol, Australia
Pro: Anja Pinborg, Denmark
17:20-17:40 Comparing fresh and frozen embryo transfers in IVF; Cost effectiveness analysis
Ben Mol, Australia
17:40-18:20 Debate: Should we measure progesterone on the day of a frozen embryo transfer?
No : Annalisa Racca, Belgium
Yes: Elena Labarta, Spain

FRIDAY, NOVEMBER 22

08:30-10:00 SCREENING OF THE MAN FOR INFERTILITY
Hall B
Capsule Have we neglected the treatment of male infertility? Can better screening improve the overall results?
Chairpersons Christopher Barratt,UK
Christopher De Jonge, USA
08:30-08:35 Introduction
Christopher Barratt, UK
08:35-09:00 Screening of the man for infertility; Why its necessary (canary in the coal mine)
Michael Eisenberg, USA
09:00-09:25 The Male Reproductive Health initiative
Christopher De Jonge, USA
09:25-09:50 Use of Social Media platforms to inform the public about male reproductive health issues
Allan Pacey, UK
09:50-10:00 Discussion
10:20-11:50 BLASTOCYSTS
Hall B
Capsule Single euploid, morphologically intact blastocyst seems like the holy grail of IVF. So why we are still debating?
Chairpersons Anja Pinborg, Denmark
Ben Mol, Australia
10:20-11:05 Debate: Blastocyst-stage embryo transfer for all
Yes: Samir Hamamah, France
No: Amelia Rodríguez-Aranda, Spain
11:05-11:30 Chromosomal mosaicism in human blastocysts: The ultimate challenge of preimplantation genetic testing?
Mina Popovic, Belgium
11:30-11:50 Prevalence of XXY karyotypes in human blastocysts: Multicenter data from 7549 trophectoderm biopsies obtained during preimplantation genetic testing cycles in IVF
Laura Rienzi, Italy
12:10-13:40 LABORATORY WORK
Hall B
Chairperson Samir Hamamah, France
11:10-12:30 IVF and the lab: Which culture medium to use
12:30-13:50 Debate: Still room for embryo morphological evaluation?
Yes: in favor Luca Ginaroli, Italy
No: against Marine Poulain, France
13:50-13:40 Time lapse
14:30-16:30 IMPLANTATION MODELS
Hall B
Capsule IVF failure is mainly due to embryonal or endometrial reasons?
Chairpersons Nick Macklon,UK
Simon Fishel, UK
14:30-14:50 Complex endometrial organoids to model embryo implantation
Emma Lucas, UK
14:50-15:15 Placental disease modelled in trophoblast organoids
15:15-15:40 Human endometrial reconstitution from somatic stem cells
15:40-16:00 Implantation Clinic: Hope or hype?
Nick Macklon, UK
16:00-16:30 Special countercurrent lecture:
Endometrial receptivity testing: Can the most reliable test stand up?
Samuel Dos Santos Ribeiro, Belgium
16:50-18:20 ADD-ON TREATMENTS
Hall B
Capsule ADD on treatments:  The best solution to keep from quitting?
Chairpersons Laura Rienzi, Italy
Scott Nelson, UK
16:50-17:35 Debate: Standard IVF vs Add-on IVF – What if the patient is willing to pay for add-ons?
Con: Joyce Harper, UK
Pro: Simon Fishel, UK
17:35-18:00 ICSI does not increase the cumulative live birth rate in non-male factor infertility
Elizabeth A. Sullivan, Australia
18:00-18:20 Is there a relationship between the time to ICSI and the reproductive outcomes?
Amelia Rodríguez-Aranda, Spain

SATURDAY, NOVEMBER 23

08:30-10:00 FERTILITY PRESERVATION
Hall B
Capsule With so many method of fertility preservation, do they all offer similar probabilities?
Chairpersons Jacques Donnez, Belgium
Michael Grynberg, France
08:30-08:50 How many eggs do we need for preserving fertility?
Nathalie Sermondade, France
08:50-09:15 Oocytes or ovarian cortex cryopreservation for fertility preservation
Jean-Philippe Wolf, France
09:15-09:35 The place of IVM for fertility preservation
Michael Grynberg, France
09:35-10:00 Ovarian tissue cryopreservation and transplantation: Still experimental?
Marie-Madeline Dolmans, Belgium
10:20-11:50 DIAGNOSIS OF INFERTILITY
Hall B
Capsule Why Should we keep doing HSG? Uterine transplantation, what kind of results can be expected?
Chairperson Rene Frydman, France
10:20-10:50 Uterine transplantation – The French experience
10:50-11:35 Debate: Hysterosalpingogram how?
Traditional oil-based HSG exploiting its therapeutic advantage: Ben Mol, Australia
Ecosy is a good alternative: Marc Even, France
11:35-11:50 Biomarkers of ovarian response
Scott Nelson, UK
12:10-13:40 QUESTIONS AND ANSWER IN HALL A
Hall B
Please go to Hall A for this session
14:30-16:30 WHAT’S NEW IN POI RESEARCH – PART 2
Hall B
Chairpersons Lisa Webber, UK
Nicholas Panay, UK
14:30-14:50 Genetics of menopause
Joop Laven, Netherlands
14:50-15:20 Genetics of POI. Novel links with DNA repair/cancer genes
Micheline Misrahi, France
15:20-15:40 Fertility and management of Turner syndrome
Sophie Christin-Maitre, France
15:40-16:00 Stem cells in and out the ovaries: Promises for POI
Gabriel Livera, France
16:00-16:30 Special countercurrent lecture